BioSpace News Archive

F-star Therapeutics, Inc. today announced new clinical data from its potentially best-in-class clinical asset FS222, a CD137/PD-L1 targeting tetravalent bispecific antibody.

Pivotal Phase 3 Trial Completed Enrollment Ahead of Schedule Enabling Topline Data Readout and NDA Filing in 2024.

SimBioSys ® highlights key advances for medical and surgical planning in breast cancer at SABCS 2022.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the first commercial shipment of the CosMx™ Spatial Molecular Imager and the AtoMx™ Spatial Informatics Platform.

MolecuLight Corp. is featured in Vizient’s newly released Tech Watch publication as a key technology for visualizing bacterial load and its locations, and helping to reduce surgical site infections.

Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19.

SQZ Biotechnologies Company (NYSE: SQZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company’s Enhanced Antigen Presenting Cell (eAPC) candidate for the treatment of HPV16+ advanced or metastatic solid tumors.

Mindset Pharma Inc. today announced that James Lanthier, CEO of Mindset, and Joseph Araujo, CSO, will participate in two upcoming conferences.

Sernova Corp. announced today that, as part of a planned leadership succession process, and after a successful 13-year tenure leading the Company through the development of its pioneering Cell Pouch System™ and ensuing growth, Dr. Philip Toleikis, President and Chief Executive Officer will be appointed Sernova’s Chief Technology Officer.

Pulmocide Ltd. today announces it has raised $52 million in a Series C extension round led by new investors.